Exelixis, Inc. (EXEL) Shares Bought by C WorldWide Group Holding A S

C WorldWide Group Holding A S lifted its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 23.9% during the fourth quarter, HoldingsChannel reports. The firm owned 352,508 shares of the biotechnology company’s stock after acquiring an additional 67,920 shares during the quarter. C WorldWide Group Holding A S’s holdings in Exelixis were worth $10,716,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Swiss National Bank increased its position in shares of Exelixis by 2.3% during the fourth quarter. Swiss National Bank now owns 500,600 shares of the biotechnology company’s stock worth $15,218,000 after purchasing an additional 11,400 shares in the last quarter. Lisanti Capital Growth LLC acquired a new stake in shares of Exelixis during the fourth quarter worth about $407,000. California Public Employees Retirement System increased its position in shares of Exelixis by 4.7% during the fourth quarter. California Public Employees Retirement System now owns 694,705 shares of the biotechnology company’s stock worth $21,119,000 after purchasing an additional 31,166 shares in the last quarter. Icon Advisers Inc. Co. increased its position in shares of Exelixis by 131.7% during the fourth quarter. Icon Advisers Inc. Co. now owns 74,149 shares of the biotechnology company’s stock worth $2,254,000 after purchasing an additional 42,149 shares in the last quarter. Finally, Teacher Retirement System of Texas increased its position in shares of Exelixis by 311.4% during the fourth quarter. Teacher Retirement System of Texas now owns 99,520 shares of the biotechnology company’s stock worth $3,025,000 after purchasing an additional 75,331 shares in the last quarter. Institutional investors and hedge funds own 80.99% of the company’s stock.

Exelixis, Inc. (NASDAQ:EXEL) opened at $28.21 on Friday. Exelixis, Inc. has a twelve month low of $18.03 and a twelve month high of $32.50. The stock has a market capitalization of $8,350.00, a PE ratio of 57.57, a P/E/G ratio of 0.83 and a beta of 1.84.

In related news, Director Alan M. Garber sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $30.30, for a total transaction of $454,500.00. Following the transaction, the director now owns 64,829 shares of the company’s stock, valued at $1,964,318.70. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 5.10% of the company’s stock.

A number of research firms have recently commented on EXEL. BidaskClub cut Exelixis from a “buy” rating to a “hold” rating in a research report on Friday, January 19th. Oppenheimer reiterated a “hold” rating on shares of Exelixis in a research report on Thursday, January 4th. Needham & Company LLC lifted their target price on Exelixis from $30.00 to $33.00 and gave the stock a “buy” rating in a research report on Tuesday, October 17th. Royal Bank of Canada lifted their target price on Exelixis from $33.00 to $39.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 17th. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $26.00 target price on shares of Exelixis in a research report on Tuesday, October 17th. Six analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $32.13.

TRADEMARK VIOLATION NOTICE: This news story was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.com-unik.info/2018/02/10/exelixis-inc-exel-shares-bought-by-c-worldwide-group-holding-a-s.html.

About Exelixis

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit